Details of the Drug
General Information of Drug (ID: DM5MKEI)
Drug Name |
2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
7,3',4'-Trihydroxyflavone; 2150-11-0; 2-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 3',4',7-Trihydroxyflavone; BRN 0253031; CHEMBL301624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-; Flavone, 7,3',4'-trihydroxy-; 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; Q-100553; 4hlf; AC1NT15U; 3',4',7-Trihydroxyflavon; SCHEMBL34405; 7, 3',4'-Trihydroxyflavone; 3'',4'',7-trihydroxyflavon; trihydroxyflavone, 7
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 270.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||